Cargando…
Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment
Autores principales: | Degner, Kenna R., Parajuli, Sandesh, Aziz, Fahad, Garg, Neetika, Mohamed, Maha, Mandelbrot, Didier A., Panzer, Sarah E., Wilson, Nancy A., Reese, Shannon R., Van Hyfte, Kristin, Zhong, Weixiong, Hidalgo, Luis G., Nickerson, Peter, Djamali, Arjang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116765/ https://www.ncbi.nlm.nih.gov/pubmed/34013117 http://dx.doi.org/10.1016/j.ekir.2021.02.033 |
Ejemplares similares
-
How Should Acute T-cell Mediated Rejection of Kidney Transplants Be Treated: Importance of Follow-up Biopsy
por: Aziz, Fahad, et al.
Publicado: (2022) -
Unusually high rates of acute rejection during the COVID-19 pandemic: cause for concern?
por: Aziz, Fahad, et al.
Publicado: (2020) -
Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients: Treatment Response Rates and Value of Early Surveillance Biopsies
por: Aziz, Fahad, et al.
Publicado: (2022) -
Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation
por: Parajuli, Sandesh, et al.
Publicado: (2017) -
Treatment of Chronic Active Antibody-mediated Rejection With Pulse Steroids, IVIG, With or Without Rituximab is Associated With Increased Risk of Pneumonia
por: Joachim, Emily, et al.
Publicado: (2020)